Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.2500 -0.0100 (-3.85%)
Streaming Delayed Price Updated: 3:37 PM EDT, Aug 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,056,914
Open 0.2535
Bid (Size) 0.2500 (477,200)
Ask (Size) 0.2506 (2,600)
Prev. Close 0.2600
Today's Range 0.2500 - 0.2673
52wk Range 0.1980 - 5.140
Shares Outstanding 9,362,444
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
From Vistagen Therapeutics, Inc.
Via GlobeNewswire
News headline image
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
From Vistagen Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-63.2%
-63.2%
1 Month
+8.2%
+8.2%
3 Month
-58.0%
-58.0%
6 Month
-52.8%
-52.8%
1 Year
-92.6%
-92.6%

More News

Read More
News headline image
The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch
Via AB Newswire
Topics Artificial Intelligence
These stocks are making the most noise in today's session. ↗
Via Chartmill
MissionIRNewsBreaks – SRX Global Inc. (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics
Via Investor Brand Network
Vistagen Therapeutics (NASDAQ:VTGN) Faces Muted Market Sentiment as Crucial PALISADE-4 Data Looms ↗
Via Chartmill
News headline image
Vistagen Appoints Douglas J. Williamson to its Board of Directors
From Vistagen Therapeutics, Inc.
Via GlobeNewswire
Unusual volume stocks in Thursday's session ↗
Via Chartmill
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2026-06-30: top gainers and losers in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
News headline image
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
News headline image
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
From Vistagen
Via Business Wire
News headline image
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
From Vistagen
Via Business Wire
News headline image
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From Vistagen
Via Business Wire
News headline image
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
From Vistagen
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire

Frequently Asked Questions

Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?
Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?
Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?
The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market
What is the current price of Vistagen Therapeutics, Inc. - Common Stock?
The current price of Vistagen Therapeutics, Inc. - Common Stock is 0.2500
When was Vistagen Therapeutics, Inc. - Common Stock last traded?
The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 08/18/26 03:37 PM ET
What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?
The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 2.34M
How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?
Vistagen Therapeutics, Inc. - Common Stock has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.